Skip to content

BetaGlue™ Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director

New Betaglue board members

Milan, May 15, 2024 – BetaGlue™ Therapeutics (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the appointment of Mike Cogswell as Chairman of the board and the appointment of Mike Maszy as Non-Executive Director.

Mike Cogswell brings over 34 years of proven expertise in all facets of international healthcare leadership, marketing, strategic planning, and new business development. As CEO and President of MagneTx Oncology Solutions Inc., Chairman of DermaCure RT and Chairman of EbaMed SA, Mike holds numerous high-profile positions in the radiation oncology space. Formerly, Mike held leadership positions as SVP Global Sales of ViewRay Inc., Mevion Medical Systems Inc. and Elekta Inc.

Mike Maszy brings over 25 years of expertise in Operations, Engineering & New Product Development of Medical Devices. Mike was former SVP Operations at Shockwave Medical (NASDAQ: SWAV), VP Manufacturing at Endologix (NASDAQ: ELGX) and Trivascular (NASDAQ: TRIV) in addition to holding roles at Medtronic in Neurosurgery, Endovascular, Peripheral & Surgical Technologies.

Mike Cogswell commented: “I’m excited to take a leadership role in this organization, accompanied by a skilled CEO in Colin, and working closely with a committed board of directors. We are entering the next phase of the business, where BetaGlue will come together to deliver a revolutionary business model and incredible value to our patients, clinicians, teammates, and shareholders.”

Mike Maszy commented: “I’m honoured to join BetaGlue Therapeutics’ board at this pivotal time in the Company’s development. I’m excited about the promise of YntraDose™ as a platform technology that benefits patients across a broad range of oncology indications and I look forward to working with my fellow directors and the capable team to help the Company realize its full potential.”

BetaGlue’s CEO, Dr. Colin Story commented: “On behalf of the whole Company I would like to extend a very warm welcome to both Mike Cogswell and Mike Maszy. Their deep and varied international experience will undoubtedly further strengthen BetaGlue’s board and support our mission to bring YntraDose to solid tumour cancer patients. I would also like to express my heartfelt thanks to Dr. Riccardo Palmisano for his dedicated services to the Company as Chairman for the past three years and also to Mr. Luca Melindo as Non-Executive Director for the past year.”


About BetaGlue Technologies S.p.A.

BetaGlue Therapeutics is an Italian clinical-stage oncology company developing a novel radiotherapy platform technology for the localised and targeted treatment of unresectable solid tumours called YntraDose. BetaGlue enjoys the support of a global Clinical Advisory Board, as well as of leading national and international advisers, in the development of its products.

Website: / Contact us: LinkedIn: Here